KLK3 and prostate carcinoma: In past clinical trials1–14 of IAS, after starting the hormone therapy, the therapy is stopped when the value of prostate specific antigen (PSA), a serum tumor marker in blood for prostate cancer, decreases to less than a predefined lower threshold value and the period of the hormone therapy becomes 6 or 9 months or above.